Russia’s seaborne air defense system to receive three types of missilesMilitary & Defense April 24, 13:09
Press review: Le Pen-Macron duel and Western-style populism in RussiaPress Review April 24, 13:00
Attorney says no attempts from Trump administration to contact SnowdenWorld April 24, 12:59
WWII Berlin offensive operation staged in MoscowSociety & Culture April 24, 12:37
Testing of Russian air defense system Vityaz to be completed by 2017Military & Defense April 24, 12:31
Moscow interested in restoring ties with EURussian Politics & Diplomacy April 24, 11:51
Russia ready to build up friendly relations with France — KremlinRussian Politics & Diplomacy April 24, 11:47
Poll shows most Russians support cancellation of Eurovision broadcastSociety & Culture April 24, 11:32
Erdogan hopes to discuss contract on S-400 missile systems with PutinMilitary & Defense April 24, 11:04
VIENNA, Austria, March 7, 2016/PRNewswire/. European pharmacists will have an opportunity to learn more about the fully automated IV compounding system and how it can significantly improve patient and hospital staff safety.
NEVO Europe [http://www.nevo-europe.com], a specialist in IV compounding automation solutions, will promote RIVA, the world's only fully automated IV compounding system at the EAHP Congress 2016 [http://www.eahp.eu/congresses], which will take place in Vienna on March 16-18, 2016.
NEVO Europe will provide information about the innovative automated IV compounding technology at the 21st Congress of the European Association of Hospital Pharmacists at booth #19.
Representatives of NEVO Europe will meet with hospital pharmacists and distributors from all over Europe to discuss the advantages of RIVA [http://www.nevo-europe.com/solutions/riva ], which prepares IV admixtures for both general medications and hazardous preparations in syringes and bags in an aseptic environment. By using RIVA, hospitals can enhance patient safety, lower cost-per-dose of medications and cut waste.
A recent study [http://ejhp.bmj.com/content/23/1/50.abstract] indicates that legislation and guidance concerning reconstitution of parenteral (IV) medicines are either nonexistent or insufficient in most countries belonging to the Council of Europe.
Researchers noted that European patients' health was at risk due to poor reconstitution and compounding practices. These risks include microbiological contamination, incorrect product composition, and health and safety issues.
"All critical compounding manipulation issues, including wrong drug, wrong dose, wrong diluents and possible microbial contamination, are addressed by RIVA," said Efi Gross, CEO of NEVO Europe. "EAHP will provide us with an opportunity to show European hospital pharmacists how they can use IV compounding automation to improve patient safety and reduce injury among hospital pharmacy staff."
RIVA is engineered to accurately and safely increase efficiency for routine repetitive movements related to the compounding of many frequently prescribed admixtures.
NEVO Europe's team at EAHP will help visitors calculate and evaluate--tailored to their hospital's environment and needs--how RIVA can optimize compounding efficiency in their own facilities.
About NEVO Europe
NEVO Europe is a leading provider of IV compounding automation technology and healthcare solutions to the European market.
Our flagship product is RIVA, the world's only fully automated IV compounding system, which prepares syringes and IV bags in a compliant, aseptic environment.
For more information and to schedule meetings with us at EAHP 2016, visit http://www.nevo-europe.com
Business Development & Marketing Manager